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Abstract
Purpose In a preimplantation genetic diagnosis for aneuploidy
(PGD-A) program, the more embryos available for biopsy, con-
sequently increases the chances of obtaining euploid embryos
to transfer. The aim was to increase the number of viable eu-
ploid blastocysts in patients undergoing PGD-A using fresh
oocytes together with previously accumulated vitrified oocytes.
Methods Sixty-nine patients with normal ovarian reserve
underwent PGD-A for repeated implantation failure or recurrent
pregnancy loss indication. After several cycles of ovarian stimu-
lation, 591 accumulated vitrified oocytes and 463 fresh oocytes
were micro-injected with the same partner’s semen sample.
PGD-A was completed on 134 blastocysts from vitrified/
warmed oocytes and 130 blastocysts from fresh oocytes.
Results A mean of 9.6% euploid blastocyst per micro-injected
vitrified/warmed oocytes and 11.4% euploid blastocyst per
micro-injected fresh oocytewere obtained (p> 0.05). The euploi-
dy and aneuploidy rates were comparable in blastocysts obtained
from micro-injected vitrified/warmed oocytes and fresh oocytes
(42.5 versus 40.8% and 57.5 versus 59.2%, p > 0.05).
Implantation rates of euploid blastocysts were comparable be-
tween the two sources of oocytes (56.0% from vitrified/
warmed oocytes versus 60.9% from fresh oocytes, p > 0.05).
Conclusions Oocyte vitrification and warming do not gener-
ate aneuploidy in blastocysts. The number of viable euploid
embryos for transfer can be increased by using accumulated
vitrified oocytes together with fresh oocytes in ICSI.
Trial registration NCT02820415 ClinicalTrials.gov
Keywords Aneuploidy . Next generation sequencing .
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Introduction
In in vitro assisted reproduction, the failures in terms of clin-
ical pregnancy and take home baby rate are mainly due to the
transfer of embryos with undiagnosed aneuploidies. The cor-
relation between the aneuploidy probability in the conceptus
and the increasing maternal age has been well established [1].
Preimplantation genetic diagnosis for aneuploidy (PGD-A)
relies on chromosomal profiling of embryos prior to implan-
tation with the aim of transferring in utero only euploid em-
bryos. PGD-A found a field of application in those patient
groups with normal karyotypes and the lowest chance of take
home baby rate. These patients are grouped in advanced ma-
ternal age (AMA), recurrent implantation failure (RIF), recur-
rent pregnancy loss (RPL), and severe male factor (SMF) [2].
Although widely practiced throughout the world, the effica-
cy of PGD-A was contested in 2007 because it was shown to
decrease the success rates of in vitro fertilization [3, 4] when
embryo biopsy was practiced on day 3 and chromosomal con-
tent was verified by fluorescent in situ hybridization. In current
practice, the technical approaches of PGD-A have changed and
overcome previous technical limitations. Advances in embryo
culture make embryo biopsy applicable at the blastocyst stage
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(days 5–7); as a consequence, it is possible to biopsy a higher
number of (trophectoderm) cells maintaining good embryonic
implantation potential [5] and increasing the accuracy of genet-
ic analysis [6, 7]. Several comprehensive chromosomal screen-
ing methods were applied for chromosomal diagnosis from
single cells such as comparative genome hybridization array
[8], single nucleotide polymorphism arrays with full molecular
karyotyping [9, 10], qPCR that tests the chromosomes present
based on few neutral amplifications per chromosome [11], and
next-generation sequencing (NGS) where complete chromo-
somal content, enabling single gene disease and mitochondrial
DNA mutations to be diagnosed at the same time [12, 13].
Encouraging results have been found from PGD-A application
using these advanced technologies.
It is well known that the ovarian reserve, the ovarian re-
sponse to gonadotrophin stimulation in terms of oocyte num-
ber and oocyte competence and the percentage of euploid
embryos drastically decrease as maternal age increases. On
the mean time, the more embryos available for biopsy conse-
quently increases the chances of obtaining euploid embryos to
transfer [14]. How can the number of blastocysts for biopsy on
days 5–6 be increased considering that the chances of
obtaining an euploid blastocyst to transfer are proportional
to the number of available blastocysts for biopsy? Does an
increased number of oocytes to micro-inject increase the num-
ber of euploid blastocysts to transfer?
In Italy, embryo accumulation by freezing is forbidden by
law [15]. The only alternative to increase the number of blas-
tocysts to diagnose is to increase the number of oocytes to
microinject. This number can be increased by accumulating
and vitrifying oocytes from repeated ovarian stimulations. In
2013, the practice committees of the ASRM and SART [16]
established that oocyte vitrification followed by rapid
warming [17] should no longer be considered as experimental
as fertilization and pregnancy rates are similar to results from
fresh oocytes in ICSI treatments. From a molecular point of
view, it was found that mRNA content in oocyte after vitrifi-
cation and warming is comparable with fresh oocytes [18] and
the morphokinetic development of embryos from fresh and
sibling vitrified/warmed oocytes are similar from the 2-cell
stage [19]. To date, there have been no studies which show
the efficacy of embryo development until blastocyst stage
from vitrified/warmed oocytes compared to fresh oocytes
from the same patients.
In the present study, we considered the hypothesis to accu-
mulate vitrified oocytes with a view to increasing the number
of oocytes for microinjection and consequently the number of
blastocyst to diagnose for patients with normal ovarian reserve
and candidate for PGD-A. They were proposed to undergo
several cycles of ovarian stimulation. In the first cycles, ma-
ture (metaphase II) oocytes were vitrified and consequently
accumulated. In the last cycle, the freshly produced mature
oocytes and the previously accumulated ones were
microinjected together with the same partner’s semen sample.
The proportion of embryo development until blastocyst stage
was compared between vitrified/warmed and fresh oocytes
from the same patients. PGD-Awas performed on blastocysts
produced from the two sources of oocytes. The comprehen-
sive chromosomal analysis of biopsied trophectoderm cells
was performed using NGS technology. The number of avail-
able euploid blastocyst and the proportion of euploid/
aneuploidy embryos vitrified/warmed from and fresh oocytes
were compared. In conclusion, we evaluated the efficacy of
oocyte accumulation by vitrification in increasing the number
of available embryos for biopsy and the number of viable
euploid embryos to transfer after PGD-A.
Material and methods
The materials and methods steps are illustrated in Fig. 1. Each
step of the protocol and the sequence of each step have been
approved by our Institutional Review Board. All participants
gave written consent on all aspects of the study after having
been informed. The present study was performed over a peri-
od of 25 months, from June 2014 to June 2016. The register
number on www.clinicaltrials.gov was NCT02820415.
Population and ovarian stimulation
The group was a compound of 69 patients aged between 29.0
and 42.3 years (mean age 36.6 years), with basal FSH on day 3
between 2.8 and 12.0 IU/l (mean 6.6 IU/l; 12.0 IU/l being the
upper limit of normal FSH - Immulite 2000, Siemens-Germany).
The indications for PGD-Awere 47 patients for RIF according to
Coughlan et al. [20] definition (transfer of at least four
good-quality embryos in a minimum of three fresh or frozen
cycles) and 22 patients for RM according to the definition of
the Practice committee of ASRM [21] (two or more pregnancy
losses). In each couple, the two partners had a normal karyotype.
The patients underwent one to two cycles of ovarian stimulation
to vitrify and accumulate oocytes and a last (second or third)
cycle of ovarian stimulation. Ovarian stimulation was performed
by the administration of recombinant FSH and LH (Gonal-F and
Luveris: Merck-Serono, London, UK or Puregon, MSD,
Franklin Lakes, USA) from cycle day 3. Initial doses were
225–300 IU/day for FSH and 75–150 IU/day for LH. Luteal
gonadotrophin-releasing hormone antagonist was given when
the leader follicle reached 14 mm in diameter with a dosage of
0.25 mg/day (Cetrotide : Merck-Serono, London, UK).
One ICSI was performed using the previously accumulated
vitrified/warmed oocytes (the first or the first and second ovar-
ian stimulations) together with the recently produced fresh
oocytes (the second or third ovarian stimulation). The mean
time between each cycle of oocyte vitrification and thawing to
microinjection was 123 days (40–273 days).
J Assist Reprod Genet
At least 2 weeks before the first ovarian stimulation, the
couples requested to know Bthe state of health of the embryos^
to the clinical director of the centre as defined in comma 5,
article 14 of the Italian law n. 40/2004 on Medically Assisted
Procreation. At the same time, they signed informed consent
forms on all procedures.
Oocyte/embryo vitrification and warming
Oocyte vitrification commenced within 1 h of oocyte pick-up.
The protocols used for oocyte [18] and embryo [25] vitrifica-
tion and warming were previously described.
ICSI on vitrified/warmed and fresh oocytes and embryo
culture
Vaginal ultrasound-guided aspiration of oocyte−cumulus
complex (OPU) was performed 35 h after human chorionic
gonadotrophin administration (HCG 10,000 IU, Gonasi:
AMSA, Rome, Italy). Oocyte denudation was performed 2 h
after oocyte retrieval. ICSI was performed 1 h after oocyte
denudation on fresh oocytes and 1 h after warming and in vitro
culture on vitrified oocytes with the same sample of partner’s
freshly ejaculated spermatozoa sample as previously de-
scribed [22].
After ICSI, in vitro culture was carried out in 25 μl of
continuous single culture complete medium with human
serum albumin (Irvine Scientific, Santa Ana, USA) under
mineral oil and in automated incubators with 5% CO2, 5%
O2 at 37 °C, fitted with time-lapse imaging acquisition
(Embryoscope, Unisense, Aarhus, Denmark). The entire
embryo development has been followed and analyzed using
morphokinetic parameters [23].
Embryo biopsy
The biopsies were performed with an Olympus IX70 inverted
microscope (UK) equipped with Hoffman optics and Narishige
manipulators (USA). TwoNarishigeMMO-202Dmanipulators
and two Narishige MM-88 micro-manipulators controlled two
pipettes, each ofwhichwas attached to an IM-6micro-injectors.
Embryo biopsies were performed on expanded or in hatching
blastocysts, grade 3 and 4 according to ASRM and ESHRE
criteria [24]. The blastocyst was immobilized with a 120 um
outer diameter holding micro-pipette in a 10 ul drop of HEPES
buffered culture medium and under mineral oil. A few
trophectoderm cells (5 to 10) were removed from a zona pellu-
cida hole using a 1.48 um diode laser (OCTAX, Bruckberg,
Germany) and a 20-um inner diameter biopsy pipette. After
the biopsy procedure, each embryo was washed in culture me-
dium and incubated until embryo vitrification and before blas-
tocyst re-expansion. The biopsied trophectoderm cells were
washed in sterile phosphate buffered saline (PBS) solution
and transferred into a 0.2-ml Eppendorf tube containing 4ul
of sterile PBS solution.
Cell lysis, whole genome amplification, and NGS protocol
The biopsied trophectoderm cells were submitted to alkaline ly-
ses and whole genome amplification according to Repli-g Single
Fig. 1 Protocol steps of PGD-A
on blastocysts from vitrified/
warmed and fresh oocytes
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Cell protocol (Qiagen, Hilden, Germany). From this part of
the protocol, all products and devices were from Life
Technologies-Thermo Fisher (Carlsbad, USA). The whole
amplified DNAwas quantified by the Qubit 2.0 fluorometer
and Qubit dsDNA HS assay kit. Libraries were prepared
from 100 ng of each sample and barcoded with IonXpress
Plus Fragment and IonXpress Barcode Adapter 1-32 or
1-16 kits. After quantification, each library was normalized
to 100 pM according to the Ion Library Equalizer kit pro-
tocol. All libraries were mixed to obtain a final concentra-
tion of 8 pM and clonally amplified with the Ion PGM
Template OT2 200 kit on the Ion OneTouch 2 System. Up
to 20 enriched libraries were loaded on Chip 16 V2. DNA
sequencing was performed on Ion PGM sequencing 200 kit
on Ion Personal Genome Machine. The updated Torrent
Suite Software was used for base calling and mapping on
human genome reference sequence hg19. For each chromo-
some read coverage was corrected by guanine-cytosine cal-
culation. Aneuploidy was diagnosed comparing data to
baseline values multiple male samples. In all the process,
a positive control with normal male DNA and a negative
control from biopsy culture media were processed together
with the samples to diagnose. Genetic analysis was validat-
ed when median absolute pairwise difference (MAPD) was
inferior to 0.3. Chromosomal segments as short as 7 Mb
could be detected.
The protocol was previously validated on single cells from
amniocytes with the following karyotypes: 45,X0, 46,XX;








Endometrial preparation for embryo transfer
After warming, single blastocysts were cultured until blas-
tocyst re-expansion. Single embryo transfers of warmed
euploid blastocyts were performed on natural cycle at
7 days after LH surge or on day 5 of progesterone admin-
istration after E2 priming in an hormonal replacement
therapy cycle.
Statistical analysis
The statistical significances between the rates from vitrified/
warmed and fresh oocytes were evaluated by z-test with
p > 0.05 and 0.01.
Results
In vitro results
The results of oocyte vitrification, ICSI, embryo culture, and
PGD-A analysis from vitrified/warmed and fresh oocytes are
presented in Table 1.
The patients produced a mean of 7.5 metaphase II oocytes
that were vitrified during the first ovarian cycles and amean of
6.7 metaphase II oocytes that were used as fresh. The survival
rate of vitrified oocytes was 96.1% (591/615). The fertiliza-
tion rate (411/591, 69.5% versus 343/463, 74.1%, p 0.05)
was comparable between vitrified/warmed and fresh oocytes.
The proportion of biopsied blastocysts calculated on MII oo-
cytes at OPU was inferior in vitrified oocytes (138/591,
22.4%) compared to fresh oocytes (135/463, 29.2%, p 0.01).
Calculated on zygote number, these proportions (138/411,
33.6% versus 135/343, 39.4%, p 0.05) were comparable be-
tween vitrified/warmed and fresh oocytes.
Genetic testing results
The genetic analysis was validated and completed respective-
ly in 97.1 and 96.3% of the biopsied blastocysts from vitrified/
warmed and fresh oocytes (MAPD value superior to 0.3).
More than 100,000 reads were produced per sample. After
PGD-A, the euploid blastocyst rate was calculated on the
number of MII oocytes at OPU and on the number of
microinjected MII oocytes and compared between the group
of vitrified/warmed oocytes with fresh oocytes. The euploid
blastocyst rates were comparable in the two groups when cal-
culated on MII oocytes at OPU (57/615, 9.3% from vitrifed/
warmed oocytes versus 53/463, 11.4% from fresh oocytes,
p > 0.05) and on microinjected MII oocytes (respectively 57/
591, 9.6% and 53/463, 11.4%, p 0.05).
The euploid blastocyst rates calculated on the number of
completed genetic diagnosis were comparable between the
group of vitrified/warmed oocytes and the group of oocytes
used as fresh (euploid blastocyst rate: 57/134, 42.5% from
vitrified/warmed oocytes versus 53/130, 40.8% from fresh
oocytes, p 0.05).
Clinical outcomes
All warmed euploid blastocysts (25 from vitrified/warmed
and 46 from fresh oocytes) survived to warming and were
transferred one at the time. The implantation rates were com-
parable between blastocysts from vitrified/warmed oocytes
(14/25, 56.0%) and those from fresh oocytes (28/46, 60.9%,
p 0.05). Forty-eight patients had euploid embryos from both
sources of oocytes, 9 from only vitrified/warmed oocytes, 5
from only fresh oocytes. Seven patients had no euploid em-
bryo from neither vitrified/warmed nor fresh oocytes.
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To date, 34 children have been born 12 from vitrified/
warmed oocytes and 22 from fresh oocytes. Eight pregnancies
are on-going. All genetic analyses were confirmed by prenatal
or postnatal genetic diagnosis.
Discussion
We present the results of PGD-A from blastocysts obtained
from accumulated vitrified/warmed and fresh oocytes from
the same patients. Oocyte vitrification (and warming) leads to
a similar rate of fertilization, and blastocyst calculated on zygote
number. Despite 96.1% of oocyte survival rate to vitrification
process, the percentage of biopsied blastocyst calculated onMII
oocytes at OPU was inferior in vitrified oocytes (22.4%) com-
pared to fresh oocytes (29.2%, p 0.01). Calculated on zygote
number, the blastocyst rates were comparable between the two
groups. The euploidy/aneuploidy rates in blastocysts calculated
on MII oocytes at OPU or microinjected MII oocytes were
comparable in the two sources of oocytes from the same pa-
tients. Implantation rates of warmed euploid blastocysts were
comparable between the two sources of oocytes when
transferred on natural cycles. Oocyte accumulation by vitrifica-
tion increases the number of available embryos for biopsy and
hence the number of viable euploid blastocysts to transfer, in-
creasing the chances of obtaining a pregnancy.
After oocyte accumulation by vitrification and their addi-
tion to the fresh oocytes cohort, the number of expanded or
in-hatching blastocyst available for biopsy nearly doubled
(1.7 blastocyst per cycle with vitrified/warmed oocytes plus
2.0 blastocysts per cycle using fresh oocytes).
Milàn et al. [26] and Cobo et al. [27] first proposed oocyte
accumulation by vitrification as a strategy to increase the number
of oocytes for microinjection, increasing the chances of positive
outcomes in AMA and low-responder patients. As Forman et al.
[28], we found that oocyte vitrification does not increase the risk
of embryo aneuploidy nor diminish the implantation potential.
Two previous studies performed on a very limited number of
cases provided good clinical results of preimplantation genetic
analysis on vitrified blastocysts obtained from vitrified oocytes
[29, 30]. Zygote and embryo banking are also alternatives to
increase the number of embryos to biopsy and transfer [31]. In
Italy, these strategies are not applicable because embryo freezing
is only allowed when embryo transfer cannot be performed due
Table 1 Results of oocyte
vitrification/warming and ICSI,
embryo culture, PGS-A analysis,










N. patients 69 69
N. ovarian cycles to accumulate oocytes 82 69
In vitro results
Metaphase II oocytes at OPU (mean per OPU) 615 (7.5) 463 (6.7)
Vitrified oocytes 615 –
Survived oocytes (survival rate) 591 (96.1) –
Micro-injected oocytes 591 463
Zygotes (fertilization rate) 411 (69.5) 343 (74.1) NS
Expanded/hatching biopsied
Blastocysts (proportion on zygote)
138 (33.3) 135 (39.4) NS
Vitrified biopsied blastocysts 138 135
Genetic testing results
Completed genetic analysis (percentage) 134 (97.1) 130 (96.3) NS
N. euploid blastocysts (euploidy rate
on completed genetic analysis)
57 (42.5) 53 (40.8) NS
N. aneuploid blastocysts (aneuploidy
rate on completed genetic analysis)
77 (57.5) 77 (59.2) NS




Warmed, survived and transferred blastocysts 25 46
Embryo transfers 25 46
Clinical pregnancies (per embryo transfer) 15 (60.0) 30 (65.2) NS
Implanted embryos (implantation rate) 14 (56.0) 28 (60.9) NS
Arrested pregnancy 1 2
NS non-significant
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to unexpected medical causes at the moment of fertilization. In
2009 and after the sentence the Constitutional Court embryo
freezing became allowed to avoid multiple pregnancy risk due
to the transfer of several embryos [32]. To freeze and accumulate
embryos for other uses such as later diagnosis remains illegal. On
the other hand, it is permitted to accumulate oocytes. At any time
of ART treatment and before embryo transfer in utero, the couple
can request to know Bthe state of health^ of the embryos as
written in the Italian law on Medically Assisted Procreation
[15] and provided in our centre.
In the present study, comprehensive chromosomal analyses
were performed on blastocysts from the same patients, after two
or more ovarian stimulations with the same ovarian stimulation
protocol and within a limited duration (4.2 months). For 48
couples (69.6%), euploid embryos were obtained from both
vitrified/warmed and fresh oocytes. Seven couples (10.1%)
had no euploid embryo from neither vitrified/warmed nor fresh
oocytes. Nine couples (13.0%) had euploid embryos only from
vitrified/warmed oocytes and 5 couples (7.2%) only from fresh
oocytes. For these last 5 couples plus the 7 couples that had no
euploid embryo from vitrified/warmed and fresh oocytes, oo-
cyte accumulation gave no further advantage because no sup-
plementary euploid embryo was obtained from additional ovar-
ian stimulation (12/69, 17.4% of the couples). This aspect is a
limitation of the oocyte accumulation strategy that is not pre-
dictable a priori. 89.9% of the patients undergoing the present
protocol of oocyte accumulation had euploid blastocysts to
transfer. This rate is higher than in Forman et al. study [45]
where 67% of good responder patients reached embryo transfer
with fresh euploid blastocysts and without oocyte accumula-
tion. According to the IVF with PGD-A survey in the USA
for the period 2011–2012 [37], this rate varied between
53.1% for patients over 37 years old and a maximum of
77.5% for patients under 35 years old. The present strategy of
oocyte accumulation leaded to an increased proportion of pa-
tients reaching embryo transfer due to an increased number of
available euploid blastocysts.
In terms of the cost for couples, the cost of diagnosis calcu-
lated on available blastocyst was decreased of one third when
blastocysts from fresh and vitrified/thawed oocytes were
biopsied compared to blastocysts from fresh oocytes only. No
patient experienced particular discomfort as a result of multiple
ovarian stimulation for oocyte accumulation. When no euploid
blastocyst is available to transfer from successive ovarian stimu-
lations, a second biopsy on a different trophectoderm spot could
be proposed after embryo thawing to recover aneuploid/diploid
blastocysts firstly diagnosed as aneuploid [33, 34].
The concept of chromosomal diagnosis on the embryo be-
fore transfer in a view to increase implantation rate in those
patients with a poor prognosis (AMA, RIF, RM, SMF) has
been globally practiced since the 1990s. Despite accumulated
results and the yearly reports of the ESHRE PGD consortium,
the study of Mastenbroek et al. [3] made the scientific
community realise that the protocols used for embryo biopsy
and genetic analysis applied at that time were not appropriate
and decreased the chances of pregnancy [4]. Today, the situa-
tion has improved, the population that would benefit most
from PGD-A in improving pregnancy rate decreasing miscar-
riage has been mainly demonstrated for young patients, with a
good prognosis or normal ovarian reserve according to the
reviews of Dahbouh et al. [35] and Lee et al. [36].
Conversely, the analysis of a large data set showed that
PGD-A significantly decreased live-birth rates per transfer
for the youngest group of patients [37].
Duplications, deletions, de novo abnormalities regarding
entire chromosomes or small segmental chromosomal gain
and loss [38] are diagnosable by using NGS coupled with
single-gene analysis when necessary. Furthermore, NGS is
the only technology that gives the possibility to quantify mi-
tochondrial DNA that has recently appeared as an indicator of
embryonic vitality [39], mosaicism that concerns 4.8% of the
blastocysts with a percentage that can reach 50% of the
trophectoderm cells [33, 40–42], de novo translocations in
the embryo [6] and copy number variation sequencing asso-
ciated with chromosome disease syndromes [43].
In 2013, ASRM and SART [16] declared that oocyte vitri-
fication should not longer be considered as experimental for
good prognosis patients. A consensus of experts agree that
embryo development after oocyte vitrification should be the
same for the comparable population of fresh embryos [44].
Nevertheless, very few studies have compared embryo devel-
opment until blastocyst stage from fresh and vitrified/warmed
oocytes and none from the same patients. According to our
data, the blastocyst rate was statistically inferior in the vitrifi-
cation group when calculated on micro-injected oocytes but
comparable when calculated on zygote number. The results
were obtained using vitrified/warmed and fresh oocytes from
the same patients. In our clinic and from the results over the
two last years, the clinical pregnancy rates (32.2% from
vitrified/warmed oocytes versus 35.3% from fresh, p > 0.05)
and miscarriage rates (5.4% from vitrified/warmed oocytes
versus 12.4% from fresh, p > 0.05—data not published) were
comparable in ICSI from fresh and vitrified/warmed oocytes.
For this reason, oocyte accumulation by vitrification as a way
to maximize the number of euploid embryos to transfer in
PGD-A patients is actively promoted. From the present data,
the equivalent euploid blastocyst rate obtained from fresh and
vitrified/warmed oocytes from the same patients (mean age of
36.8) demonstrates that oocyte vitrification does not generate
additional aneuploidy on blastocysts.
Conclusion
The applicability of PGD-A on blastocyst relies on the number
of embryos available for biopsy. From the present results, the
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euploidy and aneuploidy rates in blastocysts from vitrified/
warmed and fresh oocytes from the same patients and within
a mean period of 4 mouths were comparable. The present
study demonstrates for the first time that oocyte vitrification/
warming processes do not generate surplus aneuploidy in the
blastocysts. The number of available blastocysts for biopsy
and consequently the number of viable euploid blastocysts
for transfer can be increased by accumulating oocytes to
microinject produced from repeated ovarian stimulations.
Warmed euploid blastocysts produced from vitrified oocytes
have an implantation potential comparable to warmed euploid
blastocysts produced from fresh oocytes. In the present, this
strategy has been validated for patients with a normal ovarian
reserve. The potentiality of this strategy remains to be
established for patients with reduced ovarian reserve and in
preimplantation genetic protocols.
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